Johnson & Johnson (JNJ) shares have a price target of $179

　　Johnson & Johnson is a global leader in the pharmaceutical, medical device and consumer health care products industries. Its key products include anti-inflammation drug Stelara, multiple myeloma and light chain amyloidosis drug Darzalex and pain relief drug Tylenol. Hardy says Darzalex, Erleada and other key cancer drugs have a promising outlook in the coming years and patent protections past 2030. In addition, he's optimistic about Johnson & Johnson's robust pipeline of additional drug candidates and the positive impact rebounding demand for elective procedures could have on the medical technology segment. CFRA has a "buy" rating and $179 price target for JNJ stock, which closed at $152.36 on Dec. 3.